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Objectives. This study sought to examine whether lipopro-
tein(a) levels predict coronary artery lumen changes in patients
with symptomatic coronary artery disease (CAD) and normal to
moderate hypercholesterolemia.
Background. Recent conflicting reports have confirmed or
refuted the association of lipoprotein(a) with clinical events or
angiographically verified disease progression.
Methods. The association between serum lipoprotein(a) and
changes in coronary artery lumen was studied in 704 men entered
into the Regression Growth Evaluation Statin Study (REGRESS),
a double-blind, placebo-controlled, quantitative angiographic
study that assessed the effect of 2 years of pravastatin treatment.
The primary end points were changes in average mean segment
diameter (MSD) and average minimal obstruction diameter
(MOD). Pavastatin- and placebo-treated patients were classified
as having progressing, regressing or stable CAD, and median
lipoprotein(a) concentrations were compared. Bivariate and mul-
tivariate regression analyses were performed in the overall patient
group and in high risk subgroups.
Results. Pravastatin treatment did not affect serum apolipopro-
tein(a) levels. Median in-trial (sampled at 24 months) apolipopro-
tein(a) levels for regressing, stable and progressing CAD were,
respectively, 130, 162 and 251 U/liter in placebo-treated patients
and 143, 224 and 306 U/liter in pravastatin-treated patients.
Predictors of MSD and MOD changes were baseline MSD and
MOD, in-trial apolipoprotein(a), in-trial high density lipoprotein
(HDL) cholesterol and baseline use of long-acting nitrates. The
multivariate models predicted 14% of MSD changes and 12% of
MOD changes; apolipoprotein(a) predicted only 2.6% and 4.8%,
respectively. However, in patients with in-trial HDL cholesterol
levels <0.7 mmol/liter, apolipoprotein(a) predicted up to 37% of
the arteriographic changes.
Conclusions. Serum lipoprotein(a) levels predict coronary ar-
tery lumen changes in normal to moderately hypercholesterolemic
white men with CAD; its atherogenicity is marked in the presence
of concomitant hypoalphalipoproteinemia.
(J Am Coll Cardiol 1997;30:1491–9)
©1997 by the American College of Cardiology
Lipoprotein(a) represents a family of low density lipoprotein
(LDL)–like lipoproteins that contain apolipoprotein B100
linked by a disulfide bridge to the highly polymorphic glyco-
protein apolipoprotein(a). In healthy subjects, serum lipopro-
tein(a) levels are known to be constant throughout life and are
mainly genetically determined (1). Lipoprotein(a) is character-
ized by an important degree of structural and functional
heterogeneity and is postulated to be both atherogenic and
thrombogenic—the former because of its high cholesterol
content, the latter because of its molecular mimicry of plas-
minogen (1,2). Its physiologic function is still unknown.
Since the discovery of lipoprotein(a) by Berg in 1963,
numerous studies (3–24) have appeared that examined the
relation between lipoprotein(a) and coronary artery disease
(CAD), including epidemiologic and clinical case-control stud-
ies that investigated the association of lipoprotein(a) levels
with the presence and severity of CAD, myocardial infarction,
restenosis after angioplasty (16) and vein graft occlusion after
coronary artery bypass graft surgery (CABG) (17). In most
studies (3–17), it was concluded from multivariate analysis that
included age, body mass index, blood pressure, cigarette
smoking, and high density lipoprotein (HDL) and LDL cho-
lesterol levels that lipoprotein(a) is an independent risk factor
for the development of CAD. However, the role of lipopro-
tein(a) in CAD has also been questioned (18–24). Some of the
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conflicting results may be explained by methodologic con-
founders (25).
Presently, evidence is accumulating that the challenge of
elevated lipoprotein(a) levels may not be as deleterious as
previously thought because it appears that whether lipopro-
tein(a) causes CAD may depend on the interaction of lipopro-
tein(a) with environmental or genetic factors: 1) Serum li-
poprotein(a) levels differ between populations, with median
lipoprotein(a) levels approximately twofold to threefold higher
in blacks than in whites (26,27). However, in the absence of
atherogenic diets, blacks exhibit low morbidity and mortality
rates resulting from CAD. Analogous, transgenic mice possess-
ing the apolipoprotein(a) gene developed atherosclerosis only
when fed an atherogenic diet but not when fed their normal
chow diet (28). 2) In a human angiographic study, Armstrong
et al. (3) reported that increased LDL concentrations mark-
edly increased the risk of CAD because of elevated lipopro-
tein(a) levels, indicating modulation of lipoprotein(a) athero-
genicity by LDL cholesterol. 3) Several case-control studies
have demonstrated a “positive” association between lipopro-
tein(a) levels and the presence or severity of CAD only in
specific patient subsets, such as those with a parental history of
myocardial infarction (6), young men with premature CAD
(8,12) and patients with hyperlipidemia (10,11). 4) More
conflicting reports have been published lately, confirming or
refuting the association of lipoprotein(a) with angiographically
verified disease progression or clinical events. Watts et al. (29)
and Marburger et al. (30) found that lipoprotein(a) correlated
poorly with arteriographic changes over time in patients who
underwent a diet and exercise program or received lipid-
lowering medication. In contrast, Terres et al. (31) demon-
strated that lipoprotein(a) correlated strongly with rapid dis-
ease progression in untreated patients. Finally, Thompson et
al. (32) showed that lowering both lipoprotein(a) and LDL
cholesterol levels in patients with familial hypercholesterol-
emia produced no greater angiographic benefit than lowering
LDL cholesterol levels alone. Consequently, the latter obser-
vations appear to detract from the causal importance of
lipoprotein(a) relative to LDL in coronary atherosclerosis.
We recently completed a large angiographic lipid inter-
vention trial (Regression Growth Evaluation Statin Study
[REGRESS]) (33). The REGRESS database provided us with
the opportunity to determine the role of lipoprotein(a) on
progression of coronary atherosclerosis in a prospective man-
ner in patients with normal to moderately elevated serum
cholesterol levels. We also compared lipoprotein(a) levels of
patients in the REGRESS trial with those of healthy control
subjects. Furthermore, we aimed to delineate in men with
normal to moderately elevated serum cholesterol levels the
setting in which lipoprotein(a) most exerts its adverse effects.
Methods
Study design and subjects. REGRESS was a prospective,
double-blind, placebo-controlled, multicenter study that as-
sessed the effect of treatment with pravastatin (40 mg/day) on
progression and regression of angiographically documented
CAD (33). Dutch male patients with symptomatic coronary
atherosclerosis who had normal to moderately elevated cho-
lesterol (4 to 8 mmol/liter) and triglyceride (,4 mmol/liter)
levels and underwent various forms of primary treatment
(percutaneous transluminal coronary angiography [PTCA],
CABG, medical treatment) were included. Patients using
lipid-lowering drugs #6 weeks before qualifying lipid measure-
ment (#12 weeks for fibric acid derivatives or hepatic hydroxy-
methyl glutaryl coenzyme A [HMG-CoA] reductase inhibitors)
were excluded. All were white. Further details of the enroll-
ment procedure, treatment and follow-up and primary treat-
ment blocks are described elsewhere (33). Lipoprotein(a),
quantified by its apolipoprotein(a) content, was determined in
a subset of patients who completed the REGRESS main study
and from whom leftover serum was available both at baseline
and at 24 months. Of the 885 patients originally enrolled in the
main trial (33), 95 could not be included in the lipoprotein(a)
substudy because of adverse events, premature study discon-
tinuation and death; in another 86, leftover serum was not
available either at baseline or at 24 months. The baseline
characteristics of the 181 patients not included in the substudy
were not significantly different from those of the 704 who were
included (p $ 0.10, data not shown). Evaluable baseline and
final coronary angiograms were available in 567 patients
(81%), a proportion similar to that in the main trial (33). For
comparison, apolipoprotein(a) levels were analyzed in 274
unrelated, apparently healthy male control subjects who had
no clinical symptoms of CAD. Entry criteria were white race;
cholesterol levels between 4 and 8 mmol/liter; 20 kg/m2 # body
mass index #30 kg/m2; no diabetes; no previous history of
coronary or cerebral infarction, PTCA, revascularization and
cancer; no intake of oral anticoagulant, antihypertensive or
lipid-lowering medication; and an intake of less than three
glasses of alcoholic beverage per day.
Quantitative coronary arteriography and clinical events.
Coronary arteriograms were analyzed by quantitative com-
puter analysis (Cardiovascular Measurement System), as de-
scribed elsewhere (33). To standardize vasomotor tone, 5 to
10 mg of isosorbide dinitrate was administered sublingually 5
to 10 min before coronary angiography. Primary end points
were 1) change in average mean segment diameter (MSD) per
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CAD 5 coronary artery disease
HDL 5 high density lipoprotein
LDL 5 low density lipoprotein
MLR 5 multiple linear regression
MOD 5 minimal obstruction diameter
MSD 5 mean segment diameter
PTCA 5 percutaneous transluminal coronary angioplasty
REGRESS 5 Regression Growth Evaluation Statin Study
4S 5 Scandinavian Simvastatin Survival Study
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patient, and 2) change in average minimal obstruction diame-
ter (MOD) per patient. If a segment or lesion was adequately
visualized in two (preferably orthogonal) projections and free
of significant foreshortening in both views, the average values
of the variables in both projections were calculated. To calcu-
late the average MSD and MOD per patient, the MSDs and
MODs of all qualifying segments or obstructions (up to 13)
were added and divided by the number of contributing seg-
ments or obstructions. Segments that were occluded or located
distal to an occlusion at either baseline or follow-up were not
included because no meaningful MSD value could be calcu-
lated for these cases. Obstructions that had progressed to
occlusion or occlusions that had recanalized were not ex-
cluded; segments distal to occlusions were excluded because no
meaningful MOD value could be calculated for segments distal
to an occlusion. Changes in MSD (n 5 562) and MOD (n 5
567) were computed using those segments considered not
influenced by PTCA or CABG during the trial (33).
Analogous to the main angiographic trial (33), patients
were categorized with regard to MOD and clinical events (i.e.,
nonfatal myocardial infarction and CAD death) as having
CAD that regressed, remained stable or progressed, as follows:
1) CAD in patients with at least one lesion worsening by
$0.4 mm or developing a lesion that reduced the lumen
diameter by $0.4 mm was categorized as progressing; 2) CAD
in patients with at least one lesion improving by $0.4 mm and
no lesions worsening $0.4 mm was classified as regressing; 3)
CAD in patients with no lesions worsening or improving by
$0.4 mm was categorized as stable. Patients with a mixture of
regressing and progressing lesions, were considered to have
progressing CAD, as well as patients who had a new clinical
event, regardless of angiographic outcome.
Specimen collection and storage. The REGRESS main
study was ongoing between January 1990 and December 1993.
Blood specimens were taken from fasting patients. Serum and
plasma were harvested locally after centrifugation. Sera for the
core Lipid Reference Laboratory, Rotterdam, The Nether-
lands, were immediately aliquotted, stored at 220°C and
shipped weekly on dry ice. On the week of arrival, sera were
thawed for regular serum lipid analyses. Aliquots for serum
apolipoprotein(a) analysis were stored frozen at 270°C for a
maximum of 2 years.
Fresh-frozen EDTA-plasma was obtained from healthy
control subjects. Sampling and randomization was done by the
Dutch Institute of Public Health (RIVM, Bilthoven, The
Netherlands). Plasma apolipoprotein(a) values were recalcu-
lated to serum apolipoprotein(a) values through multiplying by
1.03.
Laboratory measurements. Apolipoprotein(a) was mea-
sured with the Pharmacia apolipoprotein(a) radioimmunoas-
say kit (No. 10-6497-01, Kabi Pharmacia Diagnostics, Uppsala,
Sweden). According to the manufacturer, 1 U of apolipopro-
tein(a) is very approximately equal to 0.7 mg of lipoprotein(a)
mass. Serum apolipoprotein(a) determinations were per-
formed at baseline and after 24 months, and paired analyses
were available from 704 REGRESS patients (80% of those
included in the main study). Throughout the present report,
the follow-up apolipoprotein(a) values, as determined from
the blood specimens sampled at 24 months, are indicated as
in-trial apolipoprotein(a) concentrations. Interassay coeffi-
cients of variation varied between 3.5% and 7.3% for low level
control samples (130 to 200 U/liter) and between 3.3% and
5.6% for high level control samples (350 to 500 U/liter).
Because international standardization is lacking, overlapping
lots of frozen serum pools at three different levels (low,
medium and high) were analyzed throughout the substudy to
ensure “traceability” among different reagent lots. We also
verified that freezing sera at 270°C for up to 2 years did not
affect measurements of apolipoprotein(a).
Serum cholesterol, HDL cholesterol and triglycerides were
measured using standard enzymatic techniques. LDL choles-
terol was calculated using the Friedewald formula (34). Be-
cause the Friedewald formula does not account for cholesterol
associated with lipoprotein(a), estimated LDL cholesterol
(mmol/liter) was corrected by subtracting lipoprotein(a)-
cholesterol, calculated as [0.30 3 Lipoprotein(a) mass/386.65]
(35). Serum lipids were analyzed at baseline and after 2, 4, 6,
12, 18 and 24 months of treatment or placebo. In-trial serum
lipid concentrations were calculated by averaging serum lipid
values obtained per patient during the entire treatment/
placebo phase. The Lipid Reference Laboratory maintains
cholesterol and HDL cholesterol standardization through the
Lipid Standardization Program of the Centers for Disease
Control, National Heart, Lung, and Blood Institute, and fulfills
its criteria concerning accuracy and precision. The laboratory
is also a member of the U.S. Cholesterol Reference Method
Laboratory Network (36).
Blood glucose was measured with standard technology in
the local hospital laboratories at baseline and at 12 and 24
months. In-trial glucose concentrations were derived by aver-
aging 12- and 24-month glucose values. Baseline plasma fibrin-
ogen was measured centrally with an enzyme immunoassay
method (37,38).
Statistical analysis. The Student t test, Mann-Whitney test
or Pearson chi-square test was used to compare group mean
values or medians, or both. Analysis of variance or Kruskall-
Wallis tests were used to compare different patient groups. The
natural logarithms of triglycerides, fibrinogen and apolipopro-
tein(a) and the LDL cholesterol/HDL cholesterol ratio were
used to normalize distributions; baseline MOD and MOD
changes were ranked because of their skewness.
Bivariate relations were quantified with Pearson or Spear-
man rank correlation coefficients. Multiple linear regression
(MLR) analyses were used to estimate the effects of individual
variables independent of others; partial correlations were used
to quantify the relation between two variables, independent of
others. Squared partial correlation coefficients, multiplied by
100, were calculated to estimate the percentage of arterio-
graphic changes explained by individual variables. Stepwise
forward selection was used to build up the MLR model. The
criterion for a variable to enter and remain in the model was an
initial probability value in the presence of other variables not
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exceeding 0.05. F statistics were used for the selection process.
As a last step, interactions between the remaining variables in
the final model were tested. Throughout the study the adopted
significance level was p 5 0.05.
Results
Baseline characteristics. Baseline characteristics of the
704 REGRESS patients studied are presented in Table 1
(mean [6SD] age 56 6 8 years, range 31 to 70; body mass
index 26.0 6 2.7 kg/m2; systolic blood pressure 135 6
18 mm Hg, diastolic blood pressure 82 6 10 mm Hg).
Approximately 89% of participants had previously smoked,
and 28% were current smokers. Fifty-one percent of patients
were randomized to pravastatin treatment. Baseline coronary
scores could be computed for 702 patients; two baseline
angiograms were lost. The average MSD was 2.55 mm, and the
average MOD was 1.89 mm. The overall baseline median
(25th, 75th percentiles) apolipoprotein(a) concentration was
236 (91, 665) U/liter. Serum apolipoprotein(a) concentrations
were $286 U/liter in 45% and $430 U/liter in 38% of patients,
which was approximately equal to 200 and 300 mg/liter of
lipoprotein(a) mass, the generally accepted cutoff values for
elevated CAD risk. Baseline median apolipoprotein(a) levels
did not significantly differ between patients randomized to
pravastatin or placebo treatment (p 5 0.84). Mean baseline
cholesterol and HDL cholesterol levels were, respectively, 6.04
and 0.93 mmol/liter.
In the male control group (n 5 274), mean age was 50 6 7
years, body mass index 25.0 6 2.4 kg/m2, systolic blood
pressure 122 6 13 mm Hg and diastolic blood pressure 77 6
9 mm Hg (data not shown). Approximately 77% of the
participants had previously smoked, and 45% were current
smokers. Mean alcohol intake was 1.14 beverages/day. Median
(25th, 75th percentiles) apolipoprotein(a) was 136 (65, 485)
U/liter. Mean cholesterol and HDL cholesterol levels were
5.66 and 1.11 mmol/liter, respectively. After adjusting for age,
body mass index, systolic and diastolic blood pressure, alcohol
intake and smoking habits, apolipoprotein(a) mean values
were 300 U/liter in the control group versus 418 U/liter in the
REGRESS patient group (p 5 0.0004). Adjusted mean cho-
lesterol and HDL cholesterol values were, respectively, 5.71
and 1.13 mmol/liter in the control group and 6.07 and 0.92
mmol/liter in the patient group; p values for the differences
between adjusted mean values were 0.0044 and ,0.0001 for
serum cholesterol and HDL cholesterol, respectively.
In-trial serum apolipoprotein(a) levels in placebo- and
pravastatin-treated patients. Median baseline apolipopro-
tein(a) levels were 238 and 236 U/liter in the placebo and
pravastatin groups, respectively (Table 1); at study end, me-
dian apolipoprotein(a) levels in placebo- and pravastatin-
treated patients were 217 and 219 U/liter, respectively (p 5
NS, data not shown). Spearman rank correlation between
baseline and follow-up apolipoprotein(a) levels was 0.96. Al-
though pravastatin did not significantly influence median apo-
lipoprotein(a) levels, it significantly reduced mean cholesterol,
LDL cholesterol and triglyceride levels and increased mean
HDL cholesterol levels compared with placebo (p , 0.001);
the maximal pravastatin effect was reached 3 to 4 weeks after
starting therapy (33).
In-trial serum apolipoprotein(a) and metabolic variables
in patients showing progression, no change or regression
during the 2-year follow-up period. Table 2 demonstrates
median in-trial serum apolipoprotein(a) levels in patients with
regressing, stable and progressing CAD. In placebo-treated
Table 1. Baseline Characteristics of the 704 Patients From the
REGRESS Main Study
Overall
(n 5 704)
Placebo
Group
(n 5 346)
Pravastatin
Group
(n 5 358) p Value*
Clinical data
Age (yr) 56 6 8 55 6 8 57 6 8 0.03
SBP (mm Hg) 135 6 18 135 6 19 135 6 17 0.98
DBP (mm Hg) 82 6 10 82 6 10 81 6 9 0.14
BP $160/95 mm Hg 123 (18%) 64 (19%) 59 (17%) 0.48
HTN by history 193 (27%) 103 (30%) 90 (25%) 0.17
Current smoker 194 (28%) 94 (27%) 100 (28%) 0.82
Ex-smoker 624 (89%) 301 (87%) 323 (90%) 0.18
BMI (kg/m2) 26.0 6 2.7 26.2 6 2.7 25.8 6 2.8 0.10
$30 kg/m2 60 (9%) 33 (10%) 27 (8%) 0.32
Long-acting nitrates 391 (56%) 191 (55%) 200 (56%) 0.86
Beta-blockers 509 (72%) 253 (73%) 256 (72%) 0.63
Ca channel blockers 425 (60%) 207 (60%) 218 (61%) 0.77
Familial heart disease 345 (49%) 168 (49%) 177 (49%) 0.81
History of MI 327 (46%) 154 (45%) 173 (48%) 0.31
History of PTCA 44 (6.3%) 22 (6.0%) 22 (6.0%) 0.91
Angiographic data 0.51
1 VD 300 (43%) 154 (45%) 146 (41%)
2 VD 234 (33%) 114 (33%) 120 (34%)
3 VD 168 (24%) 77 (22%) 91 (26%)
MSD (mm) 2.55 6 0.40 2.56 6 0.41 2.54 6 0.38 0.47
MOD (mm) 1.89 6 0.34 1.91 6 0.34 1.88 6 0.34 0.27
Laboratory data
Apo(a) (U/liter) 415 6 422 430 6 442 400 6 402 0.86
Median 236 238 236
Total-C (mmol/liter) 6.04 6 0.87 6.06 6 0.86 6.02 6 0.88 0.56
HDL-C (mmol/liter) 0.93 6 0.23 0.92 6 0.22 0.94 6 0.23 0.28
LDL-C (mmol/liter) 4.31 6 0.79 4.32 6 0.79 4.30 6 0.79 0.61
Corrected LDL-C
(mmol/liter)†
4.09 6 0.79 4.11 6 0.77 4.07 6 0.80 0.57
TGs (mmol/liter) 1.94 6 0.71 1.97 6 0.72 1.92 6 0.69 0.47
LDL-C/HDL-C ratio 4.88 6 1.40 4.94 6 1.43 4.83 6 1.38 0.54
Blood glucose (mmol/liter) 5.36 6 1.31 5.27 6 1.15 5.44 6 1.45 0.08
Fibrinogen (g/liter) 3.36 6 1.42 3.45 6 1.43 3.28 6 1.42 0.21
*Student t test, Pearson chi-square test or Mann-Whitney test, as appropri-
ate, for pravastatin versus placebo treatment. †Corrected for lipoprotein(a)-
cholesterol and calculated as Total-C (mmol/liter) 2 HDL-C (mmol/liter) 2
[TGs (mmol/liter/2.2] 2 {[Apo(a) (U/liter) p 0.7 p 0.3]/386.65}. Data presented
are mean value 6 SD or number (%) of patients, unless otherwise indicated.
Apo(a) 5 apolipoprotein(a); BMI 5 body mass index; BP 5 blood pressure;
Ca 5 calcium; DBP 5 diastolic blood pressure; HDL-C 5 high density
lipoprotein cholesterol; HTN 5 hypertension; LDL-C 5 low density lipoprotein
cholesterol; MOD 5 minimal obstruction diameter; MSD 5 mean segment
diameter; PTCA 5 percutaneous transluminal coronary angioplasty;
REGRESS 5 Regression Growth Evaluation Statin Study; SBP 5 systolic blood
pressure; TGs 5 triglycerides; Total-C 5 total cholesterol; VD 5 vessel disease.
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patients, apolipoprotein(a) levels differed significantly among
categories; median apolipoprotein(a) levels were 1.2-fold
higher for stable CAD and 1.9-fold higher for progressing
CAD compared with regressing CAD (p 5 0.0067). Although
a similar trend was found among categories in the pravastatin-
treated group (i.e., median apolipoprotein(a) levels were 1.6-
fold higher for stable CAD and 2.1-fold higher for progressing
CAD), the differences were not significant (p 5 0.34). Overall
median apolipoprotein(a) levels were 143, 177 and 259 U/liter,
respectively, in patients with regressing, stable and progressing
CAD (p 5 0.0075, data not shown).
In placebo-treated patients, median in-trial serum lipid
levels did not differ among categories, whereas fibrinogen did
(p 5 0.038). In pravastatin-treated patients, total and LDL
cholesterol differed among groups. However, after correction
for lipoprotein(a)-cholesterol, differences in median LDL cho-
lesterol levels became insignificant.
Correlates and predictors of coronary score changes. Bi-
variate correlation analysis demonstrated that baseline MOD,
baseline MSD, baseline use of long-acting nitrates and alloca-
tion to pravastatin were significant correlates to coronary score
changes. Baseline and in-trial apolipoprotein(a) levels corre-
lated significantly with MOD changes but not with MSD
changes. In-trial serum lipid levels were more consistently and
more closely related to arteriographic changes than were
baseline serum lipid levels (data not shown).
After adjustment for the variables shown in Table 3,
apolipoprotein(a) became significantly correlated with both
MOD and MSD changes. Other predictors were in-trial HDL
cholesterol, baseline MSD, baseline MOD and baseline use of
long-acting nitrates. Overall, the MLR models predicted 14%
of MSD changes and 12% of MOD changes; by itself, in-trial
apolipoprotein(a) predicted 2.6% of MSD changes and 4.8%
of MOD changes (p , 0.01). From table 3 it becomes obvious
that because of entering in-trial serum lipid concentrations
into the model, allocation to pravastatin no longer predicted
MOD or MSD changes.
In Table 4 the magnitude of the effect of in-trial apolipopro-
tein(a) on arteriographic changes is demonstrated after adjust-
ing for significant covariates only. From the beta-coefficients of
the MLR equation it can be estimated that the mean MSD
decrease per patient is 0.022 mm/ln[apolipoprotein(a)] incre-
ment and 0.060 mm/0.5-mmol/liter HDL cholesterol decrease.
Analogously, mean MOD decrease per patient is estimated to
be 0.025 mm/ln[apolipoprotein(a)] increment and 0.038 mm/
0.5-mmol/liter HDL cholesterol decrease (derived from un-
ranked MOD data, not shown).
Table 2. Serum Apolipoprotein(a) and Other Laboratory Findings in 567 Patients With Regressing,
Stable or Progressing Coronary Artery Disease*
Pravastatin Group
Regressing CAD
(n 5 45)
Stable CAD
(n 5 108)
Progressing CAD
(n 5 128) p Value†
Apo(a) (U/liter) 143 (8–1,573) 224 (10–2,295) 306 (5–1,627) 0.34
Total-C (mmol/liter) 4.46 (3.23–7.06) 4.88 (2.78–7.31) 4.87 (3.11–9.91) 0.04
LDL-C (mmol/liter) 2.98 1.83–4.46) 3.13 (1.56–5.52) 3.28 (1.56–5.97) 0.03
Corrected LDL-C (mmol/liter) 2.69 (1.70–4.39) 2.87 (1.33–5.51) 3.12 (1.21–5.72) 0.09
HDL-C (mmol/liter) 0.99 (0.55–1.59) 0.95 (0.55–1.91) 1.03 (0.55–1.91) 0.54
LDL-C/HDL-C ratio 2.99 (1.55–6.64) 3.15 (1.09–8.49) 3.32 (1.37–10.85) 0.06
TGs (mmol/liter) 1.34 (0.48–4.32) 1.31 (0.44–5.65) 1.30 (0.45–7.10) 0.70
Blood glucose (mmol/liter) 5.3 (4.2–11.1) 5.0 (3.4–12.6) 5.20 (3.30–11.0) 0.36
Baseline fibrinogen (g/liter) 3.12 (2.04–5.91) 3.02 (1.30–8.40) 2.98 (1.16–8.42) 0.10
Placebo Group
Regressing CAD
(n 5 27)
Stable CAD
(n 5 95)
Progressing CAD
(n 5 164) p Value†
Apo(a) (U/liter) 130 (6–1,236) 162 (5–1,677) 251 (5–2,143) 0.0067
Total-C (mmol/liter) 6.30 (3.43–8.52) 6.14 (3.77–8.43) 6.06 (2.99–8.79) 0.58
LDL-C (mmol/liter) 4.34 (1.84–6.86) 4.39 (2.46–6.51) 4.37 (1.78–6.74) 0.68
Corrected LDL-C (mmol/liter)‡ 4.17 (1.82–6.76) 4.22 (2.20–6.41) 4.11 (1.69–6.67) 0.42
HDL-C (mmol/liter) 0.94 (0.58–1.82) 0.88 (0.56–1.58) 0.86 (0.42–2.14) 0.61
LDL-C/HDL-C ratio 4.62 (1.59–8.30) 4.93 (2.59–8.86) 5.05 (1.67–11.64) 0.55
TGs (mmol/liter) 1.74 (0.45–5.90) 1.57 (0.57–7.10) 1.37 (0.38–7.60) 0.10
Blood glucose (mmol/liter) 5.1 (4.1–7.1) 5.10 (3.6–10.2) 5.2 (3.4–9.0) 0.97
Baseline fibrinogen (g/liter) 2.68 (1.28–6.61) 3.19 (1.03–7.79) 3.29 (1.27–7.73) 0.038
*See methods for definition of progressing, stable and regressing coronary artery disease (CAD). †Kruskal-Wallis
test. ‡Corrected for lipoprotein(a)-cholesterol and calculated as in Table 1. Data presented are median (range) in-trial
concentrations, unless otherwise indicated. Other abbreviations as in Table 1.
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Modulation of apolipoprotein(a) atherogenicity by the li-
poprotein milieu? Apolipoprotein(a) atherogenicity was in-
vestigated in high risk subgroups (Table 5). Stratifications were
made using the 10th percentile value of in-trial HDL choles-
terol and the 90th percentile values of in-trial LDL cholesterol
(corrected), triglycerides and LDL cholesterol/HDL choles-
terol ratios (n 5 704). Table 5 demonstrates that in-trial serum
apolipoprotein(a) correlates much stronger with adjusted
MSD and MOD changes in patients with in-trial HDL choles-
terol ,0.7 mmol/liter, explaining 30% and 37%, respectively,
of their variance (p , 0.01). In contrast, in the subgroup with
in-trial LDL cholesterol $4.96 mmol/liter, only 1% and 2% of
the MSD and MOD changes could be explained by serum
apolipoprotein(a) (p 5 NS).
Modulation of apolipoprotein(a) atherogenicity by in-trial
HDL cholesterol levels is presented in Figure 1. Scattergrams
display adjusted MOD and MSD reductions versus ln[apoli-
poprotein(a)] for the two HDL cholesterol strata. The steep
slope of the regression line in the low HDL subgroup (,0.7
mmol/liter) compared with the moderate slope in the higher
HDL subgroup ($0.7 mmol/liter) reflects enhanced progres-
sion of CAD at similar apolipoprotein(a) levels in the low
HDL subgroup. In the low HDL subgroup, the intersection of
the regression lines with the line of no progression or regres-
sion coincides, for both MOD and MSD changes, with an
ln[apolipoprotein(a)] of ;2 [i.e., as low as 7 U/liter apoli-
poprotein(a)]. In the lower risk stratum, similar albeit weaker
trends were found across the measured serum apolipopro-
tein(a) range; however, no clear cutoff apolipoprotein(a) value
above which most CAD progressed could be demonstrated.
Discussion
The consistent clinical lesson from current arteriographic
trials is that patients with documented CAD benefit from
aggressive lipoprotein manipulations with regard to both cor-
onary artery lumen change and clinical events (39), irrespective
of the baseline cholesterol level. Subgroup analysis of the
Scandinavian Simvastatin Survival Study (4S) (40) showed that
percent reductions in LDL cholesterol and decreases in rela-
tive risk of coronary heart disease in patients taking simvasta-
tin were comparable and constant across all quartiles of
baseline LDL cholesterol, suggesting that the percent reduc-
tion in LDL cholesterol rather than its absolute level during
treatment was the determinant of clinical benefit. Thompson et
al. (41) further tested this hypothesis across 11 quantitative
angiographic trials and found a significant relation between
percent change in LDL cholesterol and change in percent
diameter stenosis. However, this precept was tempered by the
results of the Harvard Atherosclerosis Reversibility Project
(HARP) (42), in which lipid-lowering appeared ineffectual in
patients whose baseline values of LDL cholesterol were in the
normal range. Taken together, the 4S data and analyses of
quantitative coronary angiographic trials suggest (41) that
although lowering LDL cholesterol by 35% often helps to slow
or halt progression of atherosclerosis, it does not always do so.
This finding presumably reflects the importance of other risk
factors for which lipoprotein(a) is a candidate in promoting
lesion progression. Because only few prospective angiographic
Table 3. Relations Between Adjusted Coronary Score Changes
and Clinical and Laboratory Findings: Results of Multiple
Regression Analyses
DMSD
(n 5 562)
DMOD
(n 5 567)
Baseline MSD 0.28*
Baseline MOD 0.27*
Age 0.00 0.13†
BMI 2 0.02 2 0.01
Current smoker 0.08 0.05
Ex-smoking 0.08 0.08
SBP 2 0.08 2 0.09
DBP 0.08 0.10
Long-acting nitrates 0.22* 0.12
Pravastatin 2 0.03 2 0.07
In-trial Apo(a) 0.16‡ 0.22*
In-trial corrected LDL-C§ 0.05 0.02
In-trial HDL-C 2 0.17‡ 2 0.14†
In-trial TGs 2 0.08 2 0.01
In-trial blood glucose 0.08 0.09
Baseline fibrinogen 2 0.03 0.00
Multiple R 0.43 0.41
Adjusted R2 14% 12%
*p , 0.001. †p , 0.05. ‡p , 0.01. §Corrected for lipoprotein(a)-cholesterol
and calculated as in Table 1. Data presented are partial correlation coefficients,
adjusted for all other variables in table, for changes (D) in mean segment
diameter (MSD) and ranked minimal obstruction diameter (MOD). Other
abbreviations as in Table 1.
Table 4. Predictors of Arteriographic Changes (minimal obstruction
diameter, mean segment diameter) in the 567 Patients From the
REGRESS Main Study: Results of Stepwise Forward Multiple
Linear Regression Analysis*
Dependent Variable
Regression
Coeff (SE) p Value
Adjusted R2
(%)
DMSD
Baseline MSD 0.112 (0.024) , 0.0001 6.5
Long-acting nitrates 0.080 (0.022) 0.0003 10.1
In-trial HDL-C 2 0.120 (0.043) 0.0057 12.0
In-trial Apo(a) (ln) 0.022 (0.008) 0.0070 13.9
Constant 0.278 (0.095) 0.0036
DMOD (ranked)
Baseline MOD 0.247 (0.055) , 0.0001 5.6
In trial Apo(a) (ln) 22.47 (6.41) 0.0005 8.9
In-trial HDL-C 2 82.48 (33.11) 0.0133 10.4
Long-acting nitrates 37.81 (17.56) 0.0321 11.5
Constant 153.0 (50.47) 0.0027
*Baseline minimal obstruction diameter (MOD); baseline mean segment
diameter (MSD); age; body mass index; current and previous smoking; systolic
and diastolic blood pressures; use of long-acting nitrates; allocation to pravasta-
tin; baseline fibrinogen levels; and in-trial serum levels of apolipoprotein(a)
[Apo(a)], low density lipoprotein cholesterol, high density lipoprotein choles-
terol (HDL-C), triglycerides and blood glucose were the variables entered into
the model. Coeff 5 coefficient; D 5 change in.
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studies have hitherto examined the association of serum
lipoprotein(a) with the course of CAD (29–32,43), we aimed
to define, in a broader range of patients with documented
CAD, in which patients with lipoprotein(a) assessments had
the highest predictive value. To this end, apolipoprotein(a)
levels were determined in adequately stored leftover sera from
REGRESS patients (33).
Pooled data analysis. There are three main results of this
substudy: 1) Median baseline apolipoprotein(a) levels were
significantly elevated in the REGRESS patient group, who all
had symptomatic CAD, compared with levels in healthy con-
trol subjects (236 vs. 136 U/liter, p , 0.001); furthermore,
median in-trial apolipoprotein(a) levels were significantly
higher in patients with progressing (259 U/liter) and stable
CAD (177 U/liter) than in patients with regressing CAD (143
U/liter). 2) In-trial apolipoprotein(a) and in-trial HDL choles-
terol, but not in-trial LDL cholesterol, predicted the course of
CAD in normal to moderately hypercholesterolemic men. 3)
Apolipoprotein(a) atherogenicity was far more daunting in the
presence of concomitant low HDL cholesterol levels (,10th
percentile).
The rightward shift of the serum apolipoprotein(a) distri-
bution in the REGRESS patient group compared with that in
apparently healthy control subjects is in accordance with the
findings of numerous population and clinical studies (3–17).
The significantly higher apolipoprotein(a) levels in patients
categorized as having progressing or stable CAD than those
with regressing CAD (Table 2) are in agreement with the data
of Terres et al. (31) but in contrast with the data of Watts et al.
(29) and Marburger et al. (30). When in-trial serum lipid levels
rather than baseline lipid levels were entered into the MLR
models, both in-trial apolipoprotein(a) and in-trial HDL cho-
lesterol, but not in-trial LDL cholesterol, predicted arterio-
graphic changes (Tables 3 and 4) in this patient group. This
finding is not surprising in view of the constellation of serum
lipids present in the REGRESS population. In fact, decreased
HDL cholesterol levels (,0.90 mmol/liter), preexisting in
;50% of the REGRESS population (Table 1), and elevated
apolipoprotein(a) levels were major characteristics of its risk
profile in addition to moderate baseline hypercholesterolemia.
Moreover, the cholesterol-lowering intervention with pravasta-
tin in 50% of patients, mainly affecting LDL cholesterol levels,
further diminished the causal role of LDL as a risk factor.
Subgroup analysis. Although apolipoprotein(a) was a pre-
dictor of MSD and MOD changes in the studied REGRESS
patients, it explained only 2.6% and 4.8% of coronary score
changes (Table 3). In the case of concomitant presence of
in-trial HDL cholesterol ,0.7 mmol/liter, the strength of the
association increased greatly, predicting up to 30% and 37% of
adjusted MSD and MOD changes (Fig. 1, Table 5).
By delineating other adverse lipoprotein milieus, our results
extend the findings of Armstrong et al. (3) and Maher et al.
(44) in selected hypercholesterolemic patients in whom the
dependence of apolipoprotein(a) atherogenicity on serum
LDL cholesterol levels was described. Although modulation of
apolipoprotein(a) atherogenicity by in-trial LDL cholesterol
levels was present in the REGRESS patient group, it was less
prominent than the modulation by in-trial HDL cholesterol
(Table 5). Moreover, our data suggest that differences in
lipoprotein milieus and other covariates may explain discrep-
ancies between studies investigating the association between
lipoprotein(a) levels and CAD course (29–32). Also, whereas
Maher et al. (44) documented that arterial benefits of a
substantial (.10%) reduction in LDL cholesterol was signifi-
cant only in patients with lipoprotein(a) levels in at least the
90th percentile, we found, even at low apolipoprotein(a) levels,
a deleterious effect of the lipoprotein(a) level on coronary
lumen changes in the low HDL subgroup.
In-trial serum lipid concentrations. Because in-trial serum
lipid levels correlated more closely with changes in MOD and
MSD than baseline serum lipid levels (data not shown), in-trial
serum lipid concentrations were used throughout this report to
examine the association between apolipoprotein(a) levels and
CAD course. Also, patient data were pooled to form a single
Table 5. Correlations Between In-Trial Serum Apolipoprotein(a) Levels and Changes in Coronary Scores in Selected Strata: Results of
Bivariate and Multivariate Correlation Analyses
Stratification*
DMSD (n 5 562) DMOD (n 5 567)
No. of
Pts
Pearson
Corr Coeff
No. of
Pts
Partial
Corr Coeff†
No. of
Pts
Pearson
Corr Coeff
No. of
Pts
Partial
Corr Coeff†
HDL-C ,0.70 mmol/liter 51 0.27‡ 28 0.55§ 52 0.31§ 30 0.61\
HDL-C $0.70 mmol/liter 501 0.04 238 0.11 505 0.10‡ 242 0.18§
TGs $2.74 mmol/liter 53 0.24 20 0.44 57 0.37§ 22 0.27
TGs ,2.74 mmol/liter 499 0.04 248 0.14‡ 500 0.08 250 0.20§
LDL-C $4.96 mmol/liter¶ 60 2 0.06 32 0.01 61 2 0.01 33 0.14
LDL-C ,4.96 mmol/liter¶ 482 0.09 236 0.17‡ 486 0.13§ 239 0.23\
LDL-C/HDL-C ratio $6.11¶ 55 0.28‡ 33 0.40 56 0.12 34 0.34
LDL-C/HDL-C ratio ,6.11¶ 487 0.04 237 0.15‡ 491 0.11‡ 240 0.21§
*Cutoff values for risk stratification were based on the 10th percentile in-trial value for high density lipoprotein cholesterol (HDL-C) and the 90th percentile in-trial
values for low density lipoprotein cholesterol (LDL-C), triglycerides (TGs) and LDL-C/HDL-C ratio. †Model variables controlled for: baseline mean segment diameter
(MSD); baseline minimal obstruction diameter (MOD); age, body mass index; smoking habits; systolic and diastolic blood pressure; pravastatin treatment; use of
long-acting nitrates; baseline fibrinogen and in-trial blood glucose; but serum LDL-C, HDL-C and TG levels. ‡p , 0.05. §p , 0.01. \p , 0.001. ¶Corrected for
lipoprotein(a)-cholesterol and calculated as in Table 1. Corr Coeff 5 correlation coefficient; Pts 5 patients; D 5 change in.
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collective database because serum apolipoprotein(a) levels
were not affected by pravastatin treatment (median levels after
2 years of follow-up: 217 U/liter in control subjects vs. 219
U/liter in patients) and because allocation to pravastatin
therapy no longer predicted arteriographic changes in multi-
variate models in which in-trial serum lipid levels were entered
as covariates (Tables 3 and 4). However, so as not to overlook
any direct effect of pravastatin treatment on CAD course (45),
adjustments for allocation to pravastatin were made. The
finding that baseline use of long-acting nitrates seemed to be
independently associated with the course of CAD probably
reflected a less favorable clinical outcome in patients with
more severe disease.
Study advances and limitations. To our knowledge, this is
the first prospective angiographic study of this size in a wide
range of patients with manifest CAD and normal to moder-
ately elevated cholesterol levels to delineate the lipoprotein
milieus that restrain or reinforce apolipoprotein(a) atheroge-
nicity. Another advantage is related to the fact that LDL
cholesterol was corrected for lipoprotein(a)-cholesterol, allow-
ing us to distinguish the differential effects of these lipoproteins
on the course of CAD. Furthermore, because all apolipopro-
tein(a) measurements were performed within 2 years, apoli-
poprotein(a) results were not confounded by lipoprotein(a)
degradation due to long-term storage (25). Limitations of this
substudy are related to the fact that we do not yet know
whether the atherothrombogenicity of lipoprotein(a) is ade-
quately measured by total lipoprotein(a) or apolipoprotein(a)
concentrations alone. Future studies should investigate the
genetically determined structural or functional polymorphism
of lipoprotein(a), or both. Also, the number of major clinical
events was too small (n 5 12) to examine the association of
apolipoprotein(a) levels with patient outcome (4 [1.1%] of 358
in the pravastatin-treated group, 8 [2.3%] of 346 in the
placebo-treated group, data not shown). However, because
angiographic changes strongly correlate with future coronary
events (46–48), it is also realistic to anticipate in this popula-
tion an effect of apolipoprotein(a) levels on clinical events with
longer follow-up.
Conclusions. Lipoprotein(a) is a predictor of coronary
artery lumen changes in normal to moderately hypercholester-
olemic white men; its atherogenicity is very pronounced in the
presence of concomitant hypoalphalipoproteinemia.
We thank Jacob Seidell, PRD, RIVM, Bilthoven, The Netherlands for providing
male control samples.
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